CRx-102 Osteoarthritis Multicenter Evaluation Trial

Knee Osteoarthritis Clinical Trial

— COMET-1  

Official title:

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of CRx-102 in Subjects With Symptomatic Knee Osteoarthritis and Optional One-Year Extension

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00521989
• Other study ID #: CRx-102-006
• Status: Terminated
• Phase: Phase 2
• First received: August 27, 2007
• Last updated: March 26, 2014
• Start date: August 2007
• Est. completion date: July 2009

Study information

• Verified date: March 2014
• Source: Zalicus
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

CRx-102 is a synergistic combination drug candidate containing the cardiovascular drug dipyridamole and a very low dose of the glucocorticoid prednisolone. CRx-102 is believed to work through a novel mechanism of action in which dipyridamole selectively amplifies the anti-inflammatory and immunomodulatory activities of the glucocorticoid without replicating the dose-dependent adverse effects.

CRx-102 has been associated with clinical benefit in proof of concept studies in subjects with hand OA and RA. This is the first study to explore the efficacy of CRx-102 in knee OA. It is considered a dose-finding study and will also compare the potential benefits of CRx-102 treatment to both prednisolone administered alone and to placebo in this indication.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 279
• Est. completion date: July 2009
• Est. primary completion date: July 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Subject must voluntarily give written informed consent

• Subject must be = 40 years of age

• Knee pain for at least 6 months requiring NSAIDs or Coxibs for analgesia on the majority of days (= 15 days) during the preceding month

• WOMAC pain score when walking on a flat surface (question #1) between 30-80 mm at Screening with at least a 10 mm increase following NSAID or Coxib discontinuation during the Screening period

• Radiographic evidence of knee OA (Kellgren-Lawrence grade 2 or 3)

• Functional class I, II, or III according to the American Rheumatism Association

• Subject willing to take a multivitamin or the equivalent of at least 400 IU vitamin D and the equivalent of at least 1000 mg of elemental calcium daily

Exclusion Criteria:

• Predominant patellofemoral disease or clinically significant trauma to index knee

• History of clinically significant (as determined by the Investigator) cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, osteoporotic and/or other major disease

• History of malignancy within the past 10 years (except for excised or treated basal cell or fewer than 3 squamous cell skin carcinomas)

• History of lymphoma or chronic leukemia

• Moles or lesions that are currently undiagnosed, but are suspicious for malignancy

• Surgery within the previous 3 months (except for minor dental, and/or cosmetic procedures)

• History of drug or alcohol abuse (as defined by the Investigator)

• History of bleeding disorder

• History of GI bleeding within 5 years of Screening

• History of severe migraines or headaches

• History of glaucoma

• Visually compromising cataract

• Active diabetic retinopathy

• History of osteoporotic fracture

• History of opportunistic infection

• Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., septicemia) within 3 months prior to Screening

• Fever or symptomatic viral or bacterial infection within 2 weeks prior to Screening

• Positive for hepatitis C (HCV) antibody

• Positive for hepatitis B surface antigen (HBsAg)

• Known positive history for human immunodeficiency virus (HIV) antibody

• Surgery on the index knee within 1 year of Screening

• History of hypersensitivity to steroids or dipyridamole

• Treatment with oral, intramuscular, or intravenous glucocorticoids within 6 weeks prior to Screening; intra-articular glucocorticoids within 10 weeks prior to Screening; inhaled glucocorticoid is permitted

• Treatment with injectable hyaluronic acid within 3 months of Screening

• Treatment with another investigational drug, investigational device, or approved therapy for investigational use within 30 days prior to Screening

• Treatment with NSAIDs (oral or topical), Coxibs or topical capsaicin

• Treatment with anticoagulants including: dipyridamole, warfarin, clopidogrel, ticlopidine, or ASA > 81 mg per day

• Treatment with any concomitant medications that have not been at a stable dose for at least 28 days prior to Screening

• Treatment for osteoporosis such as bisphosphonates (e.g., Fosamax®, Actonel®), or teriparatide (e.g., Forteo®), or calcitonin (e.g., Miacalcin, Calcimar) must be at stable dosages for at least 3 months prior to Screening

• ALT or AST laboratory values >1.5 X the ULN

• HgbA1c value of >7.0%

• Current enrollment in any other study with investigational drug or device

• Female subject who is pregnant or lactating

• Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for follow-up visits on schedule

• Other unspecified reasons that, in the opinion of the Investigator or sponsor make the subject unsuitable for enrollment

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Knee Osteoarthritis
• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Drug:
• CRx-102 (2.7/90)
CRx-102 dose 1
• Prednisolone
Prednisolone
• Placebo
Placebo
• CRx-102 (2.7/180)
CRx-102 dose 2
• CRx-102 (2.7/360)
CRx-102 dose 3

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Zalicus

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline to Day 98 Using the WOMAC Pain Question #1	The WOMAC Index is a validated, 24-question self-administered assessment of three dimensions of pain, stiffness, and physical function for subjects with knee or hip OA. The WOMAC pain question #1 asks subjects to "think about the pain you felt in your (study joint) caused by your arthritis during the last 48 hours when walking on a flat surface." This is a visual analog scale (VAS) where the subject indicates pain severity by making a mark through a 100 mm horizontal line with "No Pain" on the left (0 mm) and "Extreme Pain" on the right (100 mm). The distance between the left end of the scale and the subject's mark is measured in millimeters. Lower values represent a better outcome.	Baseline to Day 98	No
Secondary	To Assess the Efficacy of the CRx-102 Compared to Placebo on the Change From Baseline to Day 98 Using the Full WOMAC Pain, Stiffness, Physical Function Parameters, and Patient Global Assessment VAS.		Day 98	No